{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T17:22:21Z","timestamp":1770139341426,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.anai.2020.06.012","type":"journal-article","created":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T09:41:10Z","timestamp":1592127670000},"page":"357-359.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["COVID-19, severe asthma, and biologics"],"prefix":"10.1016","volume":"125","author":[{"given":"Ismael","family":"Garc\u00eda-Moguel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"D\u00edaz Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Alonso Charterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Fern\u00e1ndez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Fern\u00e1ndez Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10223","key":"10.1016\/j.anai.2020.06.012_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2020.06.012_bib3","doi-asserted-by":"crossref","first-page":"105941","DOI":"10.1016\/j.rmed.2020.105941","article-title":"Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)","volume":"167","author":"Lippi","year":"2020","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.anai.2020.06.012_bib5","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jaip.2020.03.012","article-title":"COVID-19: pandemic contingency planning for the allergy and Immunology Clinic","volume":"8","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2020.06.012_bib6","first-page":"987016","article-title":"The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15","volume":"03","author":"Matsuyama","year":"2020","journal-title":"bioRxiv"},{"issue":"3","key":"10.1016\/j.anai.2020.06.012_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.resinv.2019.12.005","article-title":"Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells","volume":"58","author":"Yamaya","year":"2020","journal-title":"Respir Investig"},{"key":"10.1016\/j.anai.2020.06.012_bib8","author":"Jackson"},{"issue":"6","key":"10.1016\/j.anai.2020.06.012_bib9","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.anai.2020.06.012_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2016.07.001","article-title":"Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma","volume":"40","author":"Pelaia","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"issue":"1022 3","key":"10.1016\/j.anai.2020.06.012_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2020.06.012_bib12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijid.2020.03.013","article-title":"Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression","volume":"95","author":"Liu","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"16","key":"10.1016\/j.anai.2020.06.012_bib13","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/jama.2020.4326","article-title":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State","volume":"323","author":"Arentz","year":"2020","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.anai.2020.06.012_bib14","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2004500","article-title":"Covid-19 in critically ill patients in the Seattle region\u2014case series","volume":"382","author":"Bhatraju","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2020.06.012_bib15","first-page":"20080853","article-title":"A\u00a0cohort of patients with COVID-19 in a major teaching hospital in Europe","volume":"04.29","author":"Borobia","year":"2020","journal-title":"medRxiv"},{"issue":"15","key":"10.1016\/j.anai.2020.06.012_bib16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","article-title":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 states, 2March 1-30, 2020","volume":"69","author":"Garg","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"24","key":"10.1016\/j.anai.2020.06.012_bib17","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of COVID-19 in New York City","volume":"382","author":"Goyal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2020.06.012_bib18","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"issue":"20","key":"10.1016\/j.anai.2020.06.012_bib19","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.anai.2020.06.012_bib20","author":"Zhang"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620304075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120620304075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:25:51Z","timestamp":1761053151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120620304075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1081120620304075"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2020.06.012","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19, severe asthma, and biologics","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2020.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}